CARA

Cara Therapeutics Inc

Healthcare


Presented:07/31/2015
Price:$21.31
Cap:$0.49B
Current Price:$0.26
Cap:$0.01B

Presented

Date07/31/2015
Price$21.31
Market Cap$0.49B
Ent Value$0.18B
P/E RatioN/A
Book Value$2.08
Div Yield0%
Shares O/S22.81M
Ave Daily Vol350,909
Short Int3.63%

Current

Price$0.26
Market Cap$0.01B
CARA Therapeutics, Inc. is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain, inflammation and pruritus. The company involves in the developing of novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without undesirable side effects typically associated with currently available pain therapeutics. Its product candidate includes I.V. CR845, Oral CR845 and CR701. CARA Therapeutics was founded by Derek T. Chalmers, Michael E. Lewis and Frédérique Menzaghi on July 2, 2004 and is headquartered in Shelton, CT.

Publicly traded companies mentioned herein: Cara Therapeutics Inc (CARA)

Highlights

The presenter is long shares of Cara Therapeutics (CARA) and sees the company’s novel peripheral kappa opioid therapeutics continuing to do well in late stage clinical trials. Michael Lewis, PhD is CARA’s Chief Scientific Officer, and has a long track record in the industry, including: co-founder of Cephalon, where he served as Director of Pharmacology and Senior Director of Scientific Affairs, and co-founder and Chief Scientific Advisor to Adolor Corporation. CARA’s lead product - CR845 - has completed three Phase 2 clinical trials in post-operative pain, and the presenter sees the potential for an oral, abuse deterrent formulation to find its way to market as well. In addition, the medication is being studied for the treatment of osteoarthritis.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.